Brought to you by 
Enzon gets rights to Elan's Abelcet for $370mm
26 Nov 2002
Executive Summary
As part of its plan to divest certain assets, Elan Corp. has exclusively licensed Enzon (therapeutics for life-threatening diseases) US, Canadian, and Japanese rights to its antifungal Abelcet (amphotericin B lipid complex injection).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com